Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion type Assertion NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_head.
- NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion wasGeneratedBy ECO_0000203 NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_provenance.
- NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion wasDerivedFrom befree-20150227 NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_provenance.
- NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion SIO_000772 8604810 NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_provenance.
- NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion evidence source_evidence_literature NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_provenance.
- NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_assertion description "[In fact, the ratio of BCL-2- to CgA-immunoreactive cells was reduced (median, 4.6%; p less than 0.0001; range, 0.9-42.0%) in sZES, a condition showing virtually no risk, unchanged (median, 55.6%; range 29.4-83.8 %) in cases of MEN-1/ZES with intermediate risk, and increased (median 87.6%; p less than 0.014; range, 48.8-199.4%) in cases of AFG, a condition at the highest risk of carcinoid.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP313027.RAFX8utn2yRtaKeUCVl-bIcb06zdSu-5h9zKF4gn4uNbM130_provenance.